Phosphagenics’ Pain Program Update
•Oxycodone Patch to proceed into Phase 2 trial
•Oxycodone patch meets primary endpoint in Phase 1 trial
•Targeted pain indications equal significant market opportunity
•Company pain portfolio includes oxymorphone, oxycodone, diclofenac and lidocaine
All good, looks like we're having separate Phase 2/Phase 3.
Ann: Phosphagenics Pain Program Update , page-2
-
- There are more pages in this discussion • 79 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add AVE (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
0.3¢ |
Change
-0.001(16.7%) |
Mkt cap ! $7.923M | |||
| Open | High | Low | Value | Volume |
| 0.3¢ | 0.3¢ | 0.3¢ | $6.5K | 2.334M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 64 | 101887759 | 0.2¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 0.3¢ | 20872825 | 7 |
View Market Depth
| Last trade - 15.15pm 12/07/2024 (20 minute delay) ? |
| AVE (ASX) Chart |